Skip to main content
Feedback to SSRN
Feedback
(required)
Email
(required)
Submit
Kunihiko Kobayashi
Saitama Medical University International Medical Center (SIMC)
Learn more about SSRN Profiles
SCHOLARLY PAPERS
1
DOWNLOADS
42
TOTAL CITATIONS
0
Feedback
Scholarly Papers (1)
Sort by:
Paper Title, A-Z
Paper Title, Z-A
Author Name, A-Z
Author Name, Z-A
Date Posted, Ascending
Date Posted, Descending
Downloads, Ascending
Downloads, Descending
Citations, Ascending
Citations, Descending
Actions:
Email selected abstracts
View:
Selected
Original List
All Versions
Hide All Versions
All Abstracts
Hide All Abstracts
(Rank)
1.
Phase 2 Study of Osimertinib in Combination with Platinum and Pemetrexed in Patients with Previously Untreated EGFR–Mutated Advanced Non–Squamous Non–Small Cell Lung Cancer: The OPAL Study
Number of pages: 32
Posted: 03 Feb 2023
Ryota Saito
,
Shunichi Sugawara
,
Ryo Ko
,
Koichi Azuma
,
Ryo Morita
,
Makoto Maemondo
,
Satoshi Oizumi
,
Kazuhisa Takahashi
,
Hiroshi Kagamu
,
Yukari Tsubata
,
Masahiro Seike
,
Toshiaki Kikuchi
,
Isamu Okamoto
,
Satoshi Morita
,
Hajime Asahina
,
Kentaro Tanaka
,
Kenji Sugio
and Kunihiko Kobayashi
Tohoku University, Sendai Kousei Hospital - Department of Pulmonary Medicine, Juntendo University, Kurume University - Department of Internal Medicine, Akita Kousei Medical Center, Iwate Medical University, National Hospital Organization Hokkaido Medical Center, Juntendo University - Department of Respiratory Medicine, Saitama University - Saitama Medical University, Shimane University - Division of Medical Oncology and Respiratory Medicine, Nippon Medical School - Department of Pulmonary Medicine and Oncology, Niigata University, Kyushu University - Kyushu University Hospital, Kyoto University - Department of Biomedical Statistics and Bioinformatics, Hokkaido University, Kyushu University - Kyushu University Hospital, Oita University and Saitama Medical University International Medical Center (SIMC)
Downloads
42
(1,170,409)
View PDF
Download
Abstract:
non-small cell lung cancer, EGFR mutation, osimertinib, platinum-based chemotherapy, pemetrexed
Feedback